Literature DB >> 32353411

The role of miR-34c-5p/Notch in epithelial-mesenchymal transition (EMT) in endometriosis.

Yajuan Luo1, Dandan Wang1, Silei Chen1, Qing Yang2.   

Abstract

Endometriosis, a common benign gynecological disease, has the growth characteristics of malignant tumors, however, the pathogenesis of this disease remains unclear. It is well known that micro ribonucleic acids (miRNAs) are involved in epithelial-mesenchymal transition (EMT), associated with the development of endometriosis. This study investigated the role of a specific miRNA, miR-34c-5p, in endometriosis. High-throughput sequencing (HTS) showed that miR-34c-5p expression was reduced in ectopic endometrium (ecEM) in patients from Northeast Asia with ovarian endometriosis. A wound healing assay and a transwell invasion assay showed that miR-34c-5p inhibits the invasion and migration of Ishikawa and End1/E6E7 endocervical cells. Dual luciferase gene reporter assays revealed that miR-34c-5p specifically targets Notch1 3 'UTR, and Western blot analyses showed that miR-34c-5p promotes E-cadherin expression but inhibits Notch1, N-cadherin and vimentin expression in Ishikawa and End1/E6E7 cell lines. These results were reversed following knockdown of miR-34c-5p. Using quantitative real time reverse transcriptase polymerase chain reaction (qRT-PCR) and western blot analyses, there was a significant reduction in the expression of Notch1 in ecEM compared with eutopic endometrium (euEM). The results of this study indicate that miR-34c-5p inhibits the progression of EMT and cell invasion and migration by targeting the Notch signaling pathway, specifically, Notch1. The findings of this study provide unique insights into the development of EMT in endometriosis and novel, potential therapeutic targets.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endometriosis; Epithelial-mesenchymal transition; High-throughput sequencing; Notch1; miR-34c-5p; microRNA

Mesh:

Substances:

Year:  2020        PMID: 32353411     DOI: 10.1016/j.cellsig.2020.109666

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  7 in total

Review 1.  Role of repressed microRNAs in endometriosis.

Authors:  Kaei Nasu; Yoko Aoyagi; Ruofei Zhu; Mamiko Okamoto; Mitsutake Yano; Kentaro Kai; Yasushi Kawano
Journal:  Med Mol Morphol       Date:  2021-08-31       Impact factor: 2.309

2.  hsa-miR-199a-3p Inhibits Motility, Invasiveness, and Contractility of Ovarian Endometriotic Stromal Cells.

Authors:  Ruofei Zhu; Kaei Nasu; Naoki Hijiya; Masato Yoshihashi; Tomoko Hirakawa; Yoko Aoyagi; Hisashi Narahara
Journal:  Reprod Sci       Date:  2021-05-13       Impact factor: 3.060

3.  Effect of miR-451 on IVF/ICSI-ET outcome in patient with endometriosis and infertility.

Authors:  Lei Wang; Jing Zhang; Hairu Sun; Xuexia Ji; Shuzhen Zhang
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

4.  LINC01116 promotes proliferation and migration of endometrial stromal cells by targeting FOXP1 via sponging miR-9-5p in endometriosis.

Authors:  Liangyi Cui; Silei Chen; Dandan Wang; Qing Yang
Journal:  J Cell Mol Med       Date:  2020-12-28       Impact factor: 5.310

5.  CircPTCH1 Promotes Migration in Lung Cancer by Regulating MYCN Expression Through miR-34c-5p.

Authors:  ZhenYu Shen; ShengHua Sun
Journal:  Onco Targets Ther       Date:  2021-09-10       Impact factor: 4.147

6.  Concentration of Serum Biomarkers of Brain Injury in Neonates With a Low Cord pH With or Without Mild Hypoxic-Ischemic Encephalopathy.

Authors:  Pratima Gaulee; Zhihui Yang; Livia Sura; Haiyan Xu; Candace Rossignol; Michael D Weiss; Nikolay Bliznyuk
Journal:  Front Neurol       Date:  2022-07-07       Impact factor: 4.086

Review 7.  Current and Future Roles of Circular RNAs in Normal and Pathological Endometrium.

Authors:  Jiajie Tu; Huan Yang; Yu Chen; Yu Chen; He Chen; Zhe Li; Lei Li; Yuanyuan Zhang; Xiaochun Chen; Zhiying Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-26       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.